RT Journal Article
SR Electronic
T1 Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.27.21256170
DO 10.1101/2021.04.27.21256170
A1 Lucaciu, L
A1 Constantine-Cooke, N
A1 Plevris, N
A1 Siakavellas, S
A1 Derikx, LAAP
A1 Jones, GR
A1 Lees, CW
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2021.04.27.21256170.abstract
AB Background and aims Evidence on the outcomes of tofacitinib therapy in real world ulcerative colitis (UC) patients is needed, as a number of these patients would not match the inclusion criteria for clinical trials. We have therefore summarised data derived from observational, real-world evidence (RWE) studies on the effectiveness and safety of tofacitinib in moderate to severe ulcerative colitis (UC) patients.Methods We searched the PubMed, EMBASE, Scopus, Web of Science and Cochrane databases for observational studies on the use of tofacitinib in UC patients, published between 30/05/2018 and 24/01/2021. Pooled induction (8-14 weeks) and maintenance (16-26 weeks) clinical response and remission rates were calculated, as well as the proportion of reported adverse events using random effects models.Results Nine studies were included, comprising 830 patients, of which 81% were previously treated with anti-TNF and 57% with vedolizumab. Induction of clinical response and remission were achieved in 51% (95% CI 41-60%) and 37% (26-45%) of patients, after a median follow-up of 8 weeks. At the end of a median follow-up of 24 weeks, maintenance of clinical response and remission were met in 40% (31-50%) and 29% (23-36%) of patients, respectively. Thirty-two percent of the patients had at least one adverse event, the most commonly reported being mild infection (13%) and worsening of UC, requiring colectomy (13%). A third of the patients (35%) discontinued tofacitinib, most frequently due to primary non-response (51%).Conclusions Tofacitinib is a safe and effective therapy in real-world UC patients, as previously reported by clinical trials.Background Tofacitinib is the first Janus kinase inhibitor (JAKi) approved for the treatment of moderate to severe ulcerative colitis (UC). Real-world data is needed to understand clinical effectiveness of new therapies.Findings Clinical response rates were consistent with those reported by OCTAVE Induction trials, showing clinical efficacy similar in real-world and controlled clinical trial cohorts. There were no major safety concerns reported.Implications for patient care The results of this meta-analysis confirm the effectiveness and acceptable safety profile of tofacitinib in a real-world, highly refractory UC population, and further support its use in clinical practice.Competing Interest StatementLL, none declared. NC-C, none declared. NP has received consultancy fees from Takeda, speaker fees and/or travel support from Abbvie, Takeda, Norgine. SS, none declared. DLAAP, none declared. GRJ, none declared. CWL has received research support from Abbvie and Gilead, consultancy fees from Abbvie, Pfizer, Janssen, Gilead, Celltrion, Pharmacosmos, Takeda, Vifor, Iterative Scopes and Trellus Health; speaker fees and/or travel support from Janssen, Abbvie, Pfizer, Dr Falk, Ferring, Hospira, Takeda.Funding StatementThis work has been supported by the ISSF3 Wellcome Trust clinical lecturer bridging award (to GRJ), the Medical Research Council & University of Edinburgh, Precision Medicine PhD studentship (MR/N013166/1, to NC-C) and the UKRI Future Leaders Fellowship (to CWL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesR code and extracted data will be made available to reproduce the meta-analysis at https://github.com/nathansam/tofameta upon acceptance by a journal.AEadverse eventsaHRadjusted hazard ratioCIconfidence intervalb.dbi-dailyIBDinflammatory bowel diseaseILinterleukinIQRinter-quartile rangeJAKiJanus-kinase inhibitorLORloss of responseMACEmajor adverse cardiovascular eventsORodds ratioPMSpartial Mayo scorePNRprimary non-responseUCulcerative colitisUCEISulcerative colitis endoscopic index of severityRCTrandomized controlled trialRWEreal-world evidenceRBSrectal bleeding scaleSCCAISimple Clinical Colitis Activity IndexVTEvenous thromboembolism.